Improved activity (synergy) of YAK540 and selective toxicity for leukemia versus non-cancer cells may allow to reduce the therapeutic dose of BTZ in combination with YAK540 (class IIa HDACI) retaining or yet improving therapeutic efficacy while reducing severe patient-associated toxicity of BTZ. Here, CASC3 is linked to cancer.